We are pleased to announce that Cellis’ Macrophage-Drug Conjugate (MDC) platform has been awarded the Pfizer Research Prize 2026 in Oncology.
The award recognizes the development of a macrophage-based approach for glioblastoma, demonstrating how immune cells can be reprogrammed to selectively exert potent anti-tumor activity while maintaining a favorable safety profile in preclinical models. The MDC platform showed robust efficacy and immune activation, highlighting its strong translational potential for next-generation cancer immunotherapies.
The underlying research was published in Science Translational Medicine:
https://www.science.org/doi/10.1126/scitranslmed.adr4058
This achievement reflects the scientific depth and innovation underlying Cellis’ therapeutic strategy.
The prize was awarded to Dr. Maciej Białasek, together with Dr. Tobias Weiss and Dr. Miaomiao Sun, in recognition of work carried out by their respective research teams.
We sincerely thank the Pfizer Research Prize Foundation for this recognition and all collaborators who contributed to this achievement.
